STRM.BIO

STRM.BIO is a private, preclinical-stage biotech founded in 2020, headquartered in Cambridge, Massachusetts, with a focus on RNA and gene therapy. The company's core technology is its megakaryocyte-derived vesicle (MV) platform, designed for precise, efficient, and repeatable in vivo delivery of genetic cargo to the bone marrow. Led by an experienced team with deep industry backgrounds, STRM.BIO aims to build a diversified pipeline from a common platform foundation, targeting significant unmet needs in rare diseases and immuno-oncology. The company is currently pre-revenue and in the platform validation and early pipeline development phase.

Megakaryocyte-derived vesicle (MV) platform: a non-viral, cell-derived delivery system for targeted in vivo delivery of genetic cargos (gene editing tools, RNA, genes for cell therapy) to the bone marrow, designed for safety, repeat dosing, and scalability.

STRM.BIO competes in the crowded non-viral gene delivery space against companies developing lipid nanoparticles (e.g., Moderna, BioNTech for mRNA, plus many startups), polymer-based systems, and other extracellular vesicle technologies. Its differentiation hinges on the unique biology of megakaryocyte-derived vesicles for bone marrow targeting.